Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$98.82 USD

98.82
666,765

+1.62 (1.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical Services

Zacks News

QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay

QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.

LabCorp (LH) to Expand Clinical Trails Access With New Pact

LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.

Medtronic's (MDT) Percept RC DBS System Secures FDA Approval

Medtronic's (MDT) latest innovation joins the Percept family, the first and only DBS system with sensing, directionality and advanced programming.

Neogen's (NEOG) Q2 Earnings Miss Estimates, 2024 View Down

Neogen's (NEOG) Q2 revenues decline year over year due to lower Animal Safety business.

Cardinal Health (CAH) Streamlines Operation With New Structure

Cardinal Health's (CAH) new reporting structure is likely to streamline operations, providing better visibility of growth areas. At-home solutions and OptiFreight Logistics are possibly the key value creators.

Here's Why Investors Should Retain Integra (IART) Stock Now

Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.

Medtronic (MDT) Wins CE Mark for MiniMed 780G With Simplera Sync

Medtronic (MDT) secures the CE Mark for the MiniMed 780G system with the disposable, all-in-one Simplera Sync CGM.

Quest Diagnostics (DGX) to Boost Lab Services With New Buyout

Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.

QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind

QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.

SenesTech's (SNES) New Partnership to Broaden Evolve's Scope

The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.

Here's Why You Should Retain National Vision (EYE) Stock Now

Investors are optimistic about National Vision's (EYE) stock, banking on strong solvency and promising future strategies.

Illumina (ILMN) Extends Partnership to Advance Cancer Test

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.

HealthEquity (HQY) Upgraded to Buy: Here's What You Should Know

HealthEquity (HQY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt

Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.

Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA

Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.

Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes

Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.

Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio

Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.

Why Is HealthEquity (HQY) Down 2.4% Since Last Earnings Report?

HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.

Bruker (BRKR) Expands Materials Science Research via New Deal

Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

Investors continue to remain optimistic about STERIS (STE) due to the prospects of the healthcare business.

Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?

Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.